

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## Health Technology Evaluation

### Equality impact assessment – Scoping

#### **Erdafitinib for treating metastatic or unresectable FGFR-positive urothelial cancer ID1333**

The impact on equality has been assessed during this evaluation according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

- People in remote or rural areas might face challenges accessing treatment centres offering testing and treatment
- There are disparities in bladder cancer outcomes between men and women, with research consistently showing that women with this disease experience higher mortality rates and worse outcomes compared to their male counterparts.
- Availability and access to FGFR alteration testing varies across the UK. There is a risk in discrimination against people where the treatment team were unable to access this.
- The recent methodological shift at NICE away from end-of-life criteria may result in older people facing indirect disadvantages

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

- Committee will consider the potential impact of geographic inequalities (in accessing both FGFR testing and treatment)

- Committee will also consider whether its recommendations could have a different impact on people protected by the equality legislation (i.e. gender and/or age) than on the wider population.
- Committee will conduct the evaluation in accordance with the current [methods manual](#).

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No changes have been made.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the stakeholder list been made?

No changes have been made.

**Approved by Associate Director (name):** ... Jasdeep Hayre  
15 April 2024

**Date:**